| scholarly article | Q13442814 |
| P50 | author | Eduard Vieta | Q20090640 |
| William B. Lawson | Q37829171 | ||
| P2093 | author name string | Fan Zhang | |
| Joseph F Goldberg | |||
| Mauricio Tohen | |||
| Marie-Christine Hardy-Bayle | |||
| Alan Breier | |||
| Robin A Emsley | |||
| Richard C Risser | |||
| Robert W Baker | |||
| Angela R Evans | |||
| Jean M Azorin | |||
| Madhav A Namjoshi | |||
| Ana Maria Gonzalez-Pinto Arrillaga | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | haloperidol | Q251347 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 1218-1226 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania | |
| P478 | volume | 60 |
| Q35236966 | Acute and long-term treatment of mania. |
| Q36649096 | Acute treatment of mania: an update on new medications |
| Q36905879 | Adjunctive treatment of acute mania: a clinical overview |
| Q34661499 | Almost all antipsychotics result in weight gain: a meta-analysis |
| Q24656287 | Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial |
| Q42702891 | Animal models for bipolar disorder: from bedside to the cage. |
| Q34553398 | Anticonvulsants and antipsychotics in the treatment of bipolar disorder |
| Q38884279 | Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management |
| Q37111491 | Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review |
| Q38077281 | Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice |
| Q36797200 | Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights |
| Q21260276 | Atypical antipsychotics in bipolar disorder: systematic review of randomised trials |
| Q36158824 | Atypical antipsychotics: newer options for mania and maintenance therapy |
| Q34547920 | Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder |
| Q57244668 | Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder |
| Q57738604 | Behandlungsmöglichkeiten der akuten Manie mit atypischen Antipsychotika |
| Q33448290 | Bipolar disorder. |
| Q36106765 | Bipolar mixed states and their treatment |
| Q41118477 | Blood lactate levels as a biomarker of antipsychotic side effects in patients with schizophrenia |
| Q34613859 | Blood lactate levels in patients receiving first- or second- generation antipsychotics. |
| Q37133288 | Burden of bipolar depression: impact of disorder and medications on quality of life |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q38042478 | Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis |
| Q33976551 | Cross-species assessments of motor and exploratory behavior related to bipolar disorder |
| Q36905876 | Depot antipsychotic medications in bipolar disorder: a review of the literature |
| Q33820164 | Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention |
| Q22242334 | Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder |
| Q36519345 | Economics of atypical antipsychotics in bipolar disorder: a review of the literature |
| Q37299210 | Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review |
| Q48716278 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania |
| Q38003197 | Efficacy of antimanic treatments in mixed states |
| Q24601815 | Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials |
| Q35999567 | Efficacy of atypical antipsychotics in bipolar disorder |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q34439747 | Elevated reward-related neural activation as a unique biological marker of bipolar disorder: assessment and treatment implications. |
| Q36634257 | Emerging drugs for bipolar disorder |
| Q36881398 | Epidemiology, diagnosis and management of mixed mania |
| Q33313524 | Evaluating dose response from flexible dose clinical trials |
| Q64039164 | From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone |
| Q24245158 | Haloperidol alone or in combination for acute mania |
| Q47381585 | Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study |
| Q36568973 | How assess drugs in the treatment of acute bipolar mania? |
| Q33529314 | Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis |
| Q36545075 | Long-term use of atypical antipsychotics in bipolar disorder |
| Q35872066 | New medication treatment options for bipolar disorders |
| Q40501461 | Olanzapine in bipolar disorder |
| Q37997775 | Olanzapine-induced weight gain in patients with bipolar I disorder: a meta-analysis. |
| Q35945257 | Olanzapine: a review of its use in the management of bipolar I disorder |
| Q56791028 | Olanzapine: review of safety 2008 |
| Q37960632 | Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review |
| Q41808917 | Pharmaceutical treatment of acute bipolar depression |
| Q42758470 | Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects |
| Q36349023 | Pharmacological treatment of mixed states |
| Q36361982 | Polytherapy in bipolar disorder |
| Q48022915 | Profile and Determinants of Disability in Psychotic Disorders in Nigeria. |
| Q34600500 | Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents |
| Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
| Q25257218 | Quality of life in bipolar disorder: a review of the literature |
| Q36177621 | Rapid cycling bipolar disorder: clinical characteristics and treatment options |
| Q37954423 | Refractoriness in bipolar disorder: definitions and evidence-based treatment |
| Q24657398 | Review of olanzapine in the management of bipolar disorders |
| Q37803220 | Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder |
| Q79951377 | Safety and efficacy of rapid dose administration of quetiapine in bipolar mania |
| Q36199036 | Safety and tolerability of emerging pharmacological treatments for bipolar disorder |
| Q46552751 | Spotlight on olanzapine in bipolar I disorder |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q35739037 | The Kraepelinian Dichotomy From the Perspective of Prenatal Infectious and Immunologic Insults |
| Q34606256 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania |
| Q37292350 | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. |
| Q28083109 | The development and course of bipolar spectrum disorders: an integrated reward and circadian rhythm dysregulation model |
| Q45070780 | The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research |
| Q44052056 | The societal cost of bipolar disorder in Sweden |
| Q37429721 | Treating bipolar disorder in the primary care setting: the role of aripiprazole |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q36099536 | Valproate in bipolar disorder: 2000 onwards |
| Q37865505 | Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. |
| Q37171035 | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. |
| Q86485574 | Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort |
| Q46202394 | Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study |
| Q80923365 | [Antipsychotic drugs and pregnancy] |
Search more.